Evaluation of fruquintinib's efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Clinical journal of gastroenterology
- Publicado em
- 20 dez 2024
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Evaluation of fruquintinib's efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials
Eric Ricardo Yonatan, Rivaldi Ruby, Alver Prasetya, Erlangga Saputra Arifin
Descritores MeSH
- Benzofurans
- Quinazolines
- Colorectal Neoplasms
- Antineoplastic Agents
- Treatment Outcome
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Progression-Free Survival
- Receptors, Vascular Endothelial Growth Factor
- Humans
Veja também
Estudos relacionados
- KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials
- Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
- Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
- Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer